TNF and Crohn disease: Since the late 1990s, the anti‐TNF agents, infliximab and adalimumab, have been recommended as the first approaches to control Crohn's disease symptoms because they have demonstrated efficacy in inducing and maintaining remission, as confirmed by our NMA, preventing disease complications and achieving mucosal healing [33].